Pacira BioSciences (PCRX) Stock Price, News & Analysis

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings or view top-rated stocks.

10 analysts have issued 1 year price objectives for Pacira BioSciences' shares. Their PCRX share price targets range from $42.00 to $57.00. On average, they expect the company's share price to reach $49.50 in the next year. This suggests a possible upside of 84.9% from the stock's current price.
View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts.

Pacira BioSciences' stock was trading at $33.74 at the beginning of the year. Since then, PCRX shares have decreased by 20.7% and is now trading at $26.77.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PCRX earnings forecast.

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its earnings results on Thursday, February, 29th. The company reported $0.71 earnings per share for the quarter, meeting analysts' consensus estimates of $0.71. The firm had revenue of $181.24 million for the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a trailing twelve-month return on equity of 12.81% and a net margin of 6.22%.

ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

Pacira BioSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million.

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Pacira BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.19%), Bridge City Capital LLC (0.13%) and Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends.

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.